Novo Seeds Portfolio Company NorthSea Therapeutics Raises USD 40 Million Series B Financing

–  Funds used to complete Phase 2b ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic

Novo Seeds, the early stage investment and company creation team of Novo Holdings, today announced that its portfolio company NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases, has successfully closed a $40 million (€36 million) Series B financing round.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH